Alnylam Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ALNY and other ETFs, options, and stocks.

About ALNY

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. 

CEO
Yvonne L. Greenstreet
CEOYvonne L. Greenstreet
Employees
2,230
Employees2,230
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2002
Founded2002
Employees
2,230
Employees2,230

ALNY Key Statistics

Market cap
60.85B
Market cap60.85B
Price-Earnings ratio
1.87K
Price-Earnings ratio1.87K
Dividend yield
Dividend yield
Average volume
905.59K
Average volume905.59K
High today
High today
Low today
Low today
Open price
$449.00
Open price$449.00
Volume
0.00
Volume0.00
52 Week high
$495.55
52 Week high$495.55
52 Week low
$205.87
52 Week low$205.87

Stock Snapshot

As of today, Alnylam Pharmaceuticals(ALNY) shares are valued at $460.54. The company's market cap stands at 60.85B, with a P/E ratio of 1868.39.

Alnylam Pharmaceuticals(ALNY) stock opened on 2025-11-18 at $449.00. The price climbed to — and dipped to —.

The Alnylam Pharmaceuticals(ALNY)'s current trading volume is 0, compared to an average daily volume of 905.59K.

In the last year, Alnylam Pharmaceuticals(ALNY) shares hit a 52-week high of $495.55 and a 52-week low of $205.87.

In the last year, Alnylam Pharmaceuticals(ALNY) shares hit a 52-week high of $495.55 and a 52-week low of $205.87.

ALNY News

Nasdaq 17h
Validea Detailed Fundamental Analysis - ALNY

Below is Validea's guru fundamental report for ALNYLAM PHARMACEUTICALS, INC. (ALNY). Of the 22 guru strategies we follow, ALNY rates highest using our Twin Mome...

Validea Detailed Fundamental Analysis - ALNY
Simply Wall St 4d
Is Amyloid Regression and Kidney Preservation Data From HELIOS-B Shifting the Investment Case for Alnylam?

Earlier this week, Alnylam Pharmaceuticals announced and presented new post hoc analyses from the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), revealing am...

Is Amyloid Regression and Kidney Preservation Data From HELIOS-B Shifting the Investment Case for Alnylam?

Analyst ratings

70%

of 30 ratings
Buy
70%
Hold
26.7%
Sell
3.3%

People also own

Based on the portfolios of people who own ALNY. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.